New CEO at Haag-Streit UK

Thomas Lenzen

Haag-Streit UK (HS-UK) has appointed Thomas Lenzen as chief executive officer (CEO) of the Haag-Streit Group.

With more than two decades of international leadership experience in the med tech industry, Thomas previously held senior leadership roles at Bausch + Lomb, where he led the Business Unit Surgical for DACH and later served as general manager for the DACH region. Most recently, he was vice president International at Haemonetics.

Thomas said: “Haag-Streit has a remarkable history of shaping ophthalmology through pioneering solutions and a strong commitment to precision and quality. I am honoured to lead the company into its next phase of growth. Together with my new colleagues around the world, I look forward to building on the strength of the current portfolio and driving our strategy forward with energy, innovation, and passion.”

Thomas succeeds Thomas Bernhard, who has led Haag-Streit as CEO since 2021. He said: “It has been a privilege to serve Haag-Streit for more than a decade, and I am proud of what we have achieved together as One Haag-Streit. I warmly welcome Thomas Lenzen as my successor and wish him every success in this exciting role.”

Haag-Streit expressed its gratitude to Thomas Bernhard for his “long-standing commitment and valuable contributions to the group”.